Holen Sie sich die Stockscreener-App
28.58
3.48%
-1.03
Handel nachbörslich:
28.70
0.12
+0.42%
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
(VERA) Trading Advice - Stock Traders Daily
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily
Evercore ISI maintains Vera Therapeutics stock with $75 target By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Overweight on Vera Therapeutics stock By Investing.com - Investing.com Canada
Evercore ISI maintains Vera Therapeutics stock with $75 target - Investing.com
Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo - MSN
Vera Therapeutics stock drops amid rival drug update - MSN
Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year LowWhat's Next? - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Vera plunges as Otsuka updates on rival therapy - MSN
Vera stock falls as Otsuka updates on IgAN drug (VERA:NASDAQ) - Seeking Alpha
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Vera Therapeutics Becomes Oversold (VERA) - Nasdaq
Vera Therapeutics stock drops amid rival drug update By Investing.com - Investing.com Australia
Vera Therapeutics stock hits 52-week low at $31.64 - MSN
Vera Therapeutics stock hits 52-week low at $31.64 By Investing.com - Investing.com Nigeria
Vera Therapeutics’ Exclusive License Agreement with Stanford University - Global Legal Chronicle
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Strategic Expansion: Vera Therapeutics Grants $5.7M in Equity Awards to Strengthen Team - StockTitan
Wolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform Recommendation - MSN
Vera Therapeutics (NASDAQ:VERA) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Now Covered by Analysts at Wolfe Research - Armenian Reporter
Vera Therapeutics Inc (VERA) Stock: Assessing the Risk and Reward - The News Heater
Wolfe Research Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Upgraded at Wolfe Research - Defense World
Vera Therapeutics initiated with an Outperform at Wolfe Research - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research Initiates Coverage on Vera Therapeutics With Outperform Rating, $49 Price Target - Marketscreener.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9%Here's Why - MarketBeat
SG Americas Securities LLC Has $857,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
The Goldman Sachs Group Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
The Goldman Sachs Group Initiates Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
SG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Goldman Sachs Initiates Vera Therapeutics at Buy With $58 Price Target -January 28, 2025 at 07:43 am EST - Marketscreener.com
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Research Analysts Set Expectations for VERA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts VERA FY2025 Earnings - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Analysts - Defense World
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):